Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy in Treating Patients With Advanced or Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed advanced or metastatic colorectal cancer~  * Unresectable disease~* At least 1 bidimensionally measurable lesion~  * At least 2 cm in perpendicular diameters~* No evidence of CNS metastases~PATIENT CHARACTERISTICS:~Age:~* 18 to 75~Performance status:~* 0-1~Life expectancy:~* At least 3 months~Hematopoietic:~* WBC at least 3,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin normal~* SGOT/SGPT no greater than 2.5 times upper limit of normal (ULN)~* Alkaline phosphatase no greater than 2.5 times ULN~Renal:~* Creatinine no greater than 1.25 times ULN~Cardiovascular:~* No clinically significant cardiac disease~* No congestive heart failure~* No New York Heart Association class III or IV heart disease~* No symptomatic coronary artery disease~* No uncontrolled cardiac arrhythmia~* No myocardial infarction within the past year~Gastrointestinal:~* No evidence of dysphagia~* No malabsorption or intestinal obstruction that would affect absorption or excretion of study drugs~* No chronic diarrhea~Other:~* No other malignancy within the past 5 years except adequately treated carcinoma in situ of the cervix or localized nonmelanoma skin cancer~* No psychiatric disability that would preclude study compliance~* No other significant medical condition~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior chemotherapy for advanced or metastatic disease~Endocrine therapy:~* Not specified~Radiotherapy:~* Not specified~Surgery:~* At least 4 weeks since prior major surgery to the gastrointestinal tract~Other:~* No concurrent therapy for history of seizures or CNS disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: ACTIVE_COMPARATOR): Irinotecan i.v. 70 mg/m2, day 1, 8, 15, 22, 29; Capecitabine p.o. 2 x 1000 mg/m2, d1-14, d22-35;
- Arm B (Type: ACTIVE_COMPARATOR): Irinotecan i.v. 240 mg/m2 day 1 and day 22; Capecitabine p.o. 2 x 1000 mg/m2, d1-14, d22-35;

Based on this trial design, predict the completion outcome and termination type (if applicable).